[February 23, 2015]

Xagenic Honored as the 2015 Life Science Company of the Year by Life Sciences Ontario

Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ system designed to inform real-time treatment decisions, today announced that Life Sciences Ontario (LSO) will present Xagenic with the "2015 Life Science Company of the Year" award at the LSO Annual Awards Gala on February 25, 2015 in Toronto.

LSO is a member-driven organization that collaborates with governments, academia, industry and other life science organizations across Canada to promote and encourage commercial success throughout the life sciences industry. Xagenic will be honored as a recipient of LSO's top award based on the Company's innovation in molecular diagnostics and outstanding achievements in the life sciences sector.

Timothy I. Still, CEO of Xagenic said, "Our team is understandably thrilled to be named the 2015 Life Science Company of the Year and, more importantly, to receive this acknowledgement from our industry peers. Our unique, lab-free approach with the Xagenic X1™ molecular diagnostic platform has positioned us to vastly improve upon both performance and ease of use compared with currently available point-of-care diagnostics. As we approach approval and commercialization in the EU, Canada, and the U.S., we aim to empower clinicians to make on-the-spot treatment decisions for patients in need. This LSO award continues to reinforce the value of our technology as we advance our commercialization efforts."

In the past year, Xagenic also received the "Frost & Sullivan (News - Alert) 2014 Innovation Leadership Award for Point-of-Care Diagnostics." Xagenic Founder nd Chief Technology Officer, Shana Kelley, was also selected as a "Top 12 Canadian Innovator" by The Globe and Mail, Canada's largest-circulation national newspaper.

"We appreciate all of the support we have received from Ontario, both in terms of recognition and accolades as well as in economic incentives and the capital support that has been instrumental in laying the necessary groundwork to bring the Xagenic X1 platform to an international customer base," said Shana Kelley, Xagenic co-founder and Chief Technical Officer. "The next step is for Xagenic to go global with our commercial footprint, and the continued provincial and national support will enable us to retain operations in Canada."

To qualify for the LSO award, Ontario-based companies must be active in life science research and development, and involved in moving innovative products into or closer to commercialization. The award is open to all companies from the life science community including, but not limited to, human health, agri-food, and industrial biotechnology. Qualifying companies are required to be pre-commercialization or early-stage commercialization and have demonstrated leadership and achieved milestones.

For more information about LSO or the annual gala visit, http://www.lifesciencesontario.ca/. Additional information about Xagenic, please visit http://www.xagenic.com/.

About Xagenic

Xagenic is a privately-held molecular diagnostics company developing the Xagenic X1™ platform, a revolutionary diagnostic system designed from its inception for use in a clinician's office. The Xagenic X1 platform will allow users to perform lab-quality molecular diagnostic tests in the physician office. With a time-to-result of 20 minutes, the system is poised to transform the way healthcare is delivered. The Company is backed by Domain Associates, CTI Life Sciences Fund, the Ontario Capital Growth Corporation, BDC Capital (News - Alert) and Qiagen. Xagenic was the 2014 Frost & Sullivan Point-of-Care Diagnostics New Product Innovation Leadership Award winner. The Company is headquartered in Toronto with a San Francisco office. For more information, please visit www.xagenic.com.

[ Back To TMCnet.com's Homepage ]